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Efficacy and Tolerability of Anticholinergics in Korean Children 
with Overactive Bladder: A Multicenter Retrospective Study
We investigated the efficacy and tolerability of various anticholinergics in Korean children 
with non-neurogenic overactive bladder (OAB). A total of 326 children (males:females =  
157:169) aged under 18 yr (mean age 7.3 ± 2.6 yr) who were diagnosed with OAB from 
2008 to 2011 were retrospectively reviewed. The mean duration of OAB symptoms before 
anticholinergic treatment was 16.9 ± 19.0 months. The mean duration of medication was 
5.6 ± 7.3 months. Urgency urinary incontinence episodes per week decreased from 
1.9 ± 3.1 to 0.4 ± 1.5 times (P < 0.001). The median voiding frequency during daytime 
was decreased from 9.2 ± 5.4 to 6.3 ± 4.2 times (P < 0.001). According to 3-day voiding 
diaries, the maximum and average bladder capacity were increased from 145.5 ± 66.9 to 
196.8 ± 80.3 mL and from 80.8 ± 39.6 to 121.8 ± 56.5 mL, respectively (P < 0.001). On 
uroflowmetry, maximum flow rate was increased from 17.6 ± 8.4 to 20.5 ± 8.2 mL/sec 
(P < 0.001). Adverse effects were reported in 14 (4.3%) children and six children (1.8%) 
discontinued medication due to adverse effects. Our results indicate that anticholinergics 
are effective to improve OAB symptoms and tolerability was acceptable without severe 
complications in children.
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INTRODUCTION
Overactive bladder (OAB), or involuntary contraction of the detrusor muscle during 
the filling phase, is distressing for patients and physicians alike. Up to 20% of 4 to 6-yr-
old children have daytime wetting, and 3% of them experience wetting episodes more 
than twice a week (1). The International Continence Society, in 2002, defined a symp-
tomatic OAB as urinary urgency (a sudden and compelling desire to urinate), with or 
without urgency urinary incontinence (UUI), usually with frequency and nocturia, in 
the absence of pathologic or metabolic factors that would explain these symptoms (2). 
OAB is characterized by the presence of unstable bladder when urodynamic investiga-
tion shows involuntary detrusor contractions during the bladder filling phase, which 
may be spontaneous or provoked (3). Although the subjective hallmark of OAB is ur-
gency (4), the objective diagnosis is based on the urodynamic findings revealing the 
involuntary bladder contractions caused by detrusor overactivity (DO) while patients 
are attempting to suppress voiding. 
 The first-line treatment of non-neurogenic OAB symptoms typically begins with con-
servative measures and urotherapy, including a bladder training regimen, treatment of 
constipation, timed voiding, behavioral modifications, pelvic floor physiotherapy, and 
electrical stimulation. For children whose symptoms persist, anticholinergic medica-
tions are often added to decrease DO via blockade of bladder M3 muscarinic receptors 
(5). The use of anticholinergic medications in treatment of OAB for children has not 
been studied extensively, however, 30%-40% of children were reported to have no re-
sponse to the anticholinergics (6). Common adverse events reported in children were 
also typical of the antimuscarinic drug class, such as dry mouth and constipation (7-10). 
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 In Korea, currently oxybutynin chloride among various anti-
muscarinics is the only anticholinergic agent approved by the 
Korea Food and Drug Administration (FDA) for OAB in chil-
dren. As there are limited data on the use of anticholinergics in 
pediatric patients with OAB, little is known about the benefits 
and tolerability of anticholinergics. Therefore, the aim of this 
study was to retrospectively investigate the efficacy and tolera-
bility of anticholinergics used in Korean children with OAB.
MATERIALS AND METHODS
Study design and patients
A total of 347 patients diagnosed with lower urinary tract symp-
tom (LUTS) between January 2008 and December 2011 was 
enrolled from 15 hospitals, and 326 patients who were suitable 
for inclusion criteria were retrospectively analyzed. The follow-
ing clinical data were documented: age and gender of the pa-
tients, associated voiding symptoms, duration of symptoms, 
anticholinergics used, dosage of anticholinergics, duration of 
anticholinergics, baseline urgency, urgency incontinence, and 
frequency, the maximum and average bladder capacity, results 
of uroflowmetry, adverse effects, and treatment outcomes. A 
careful history focused on urinary symptoms, physical exami-
nation, and urinanalysis were obtained from all patients. Void-
ing diary and uroflowmetry with residual urine check were also 
performed for some selected patients. 
 Among 326 children, there are 157 boys and 169 girls (mean 
age, 7.3 ± 2.6 yr; range, 5-18 yr). The mean duration of OAB symp-
toms before anticholinergic treatment was 16.9 ± 19 months 
(Table 1). There were no statistical differences in age or gender 
according to the types of anticholinergics. Propiverine was used 
for 189 patients (58%); oxybutynin was used for 54 patients (16.6%); 
fesoterodine was used for 32 patients (9.8%); tolterodine was 
used for 28 patients (8.6%); solifenacin was used for 23 patients 
(7%). The mean duration of medication was 5.6 ± 7.3 months, 
and the mean duration of follow-up was 9.8 ± 11.6 months. All 
the variables of the patients were compared between pretreat-
ment and post-treatment with anticholinergics for OAB. The ef-
ficacy and tolerability were evaluated after anticholinergic treat-
ment.
Inclusion and exclusion criteria
All the patients were treated with an anticholinergic agent for 
more than 1 week. Patients younger than 5 or older than 19 yr 
were excluded from this study. Children with neuropathic blad-
der, spinal dysraphism, anatomical abnormalities (e.g., posteri-
or urethral valves or vesicoureteral reflux), and bowel elimina-
tion problems (e.g., constipation or encopresis) were excluded. 
Patients who had had or were being treated for primary mono-
symptomatic nocturnal enuresis, patients with urinary tract in-
fection, patients who were taking other anticholinergics or drug 
with anticholinergic-like effects, patients with the kidney, liver, 
intestine, cardiovascular system and psychological problems 
and patients with dysfunctional voiding in emptying phase were 
also excluded from this study. Patients who were allergic to or 
contraindicated to anticholinergic agents were also excluded.
Definitions in terminology
According to the International Continence Society and the In-
ternational Children’s Continence Society (2, 4), OAB was de-
fined as urgency with or without urge incontinence, usually 
with increased daytime frequency and nocturia. Urinary incon-
tinence was defined as the involuntary loss of urine, objectively 
demonstrable, and constituting a social or hygienic problem 
(11). UUI was defined as the complaint of involuntary leakage 
accompanied by or immediately preceded by urgeny (3). Clini-
cal improvement of urgency and UUI was defined as the reply 
of “no urgency” and “90% or over improved” to the question 
about symptom severity after anticholinergic treatment from 
patients or their parents, respectively.
Statistical analyses 
Statistical analyses were performed with SPSS for Windows ver-
sion 18.0 (SPSS, Chicago, IL, USA). A paired t-test was used to 
compare the parameters in the pretreatment and posttreatment 
of anticholinergics. Descriptive statistics are expressed as mean ±  
standard deviation. The chi-square test, Fisher exact test and 
ANOVA were used to complete the statistical determinations. 
All statistical analyses were 2-sided and P < 0.05 was considered 
statistically significant. 
Ethics statement
This study was approved by the institutional review board of 
our institution (UUH IRB no. 2012086). Clinical data were ob-
tained by the retrospective review of the medical records of all 
of the patients. Therefore, the institutional review board permit-
ted this study without requiring informed consent.
Table 1. Patient and clinical characteristic
Variables Findings No. according to dosage of drug
No. of patients 326
Age (yr) 7.3 ± 2.6
Gender           Male
                      Female
157
169
Symptom duration (months) 16.9 ± 19.0
No. of anticholinergics (%) 
   Propiverine
   Oxybutynin
   Fesoterodine
   Tolterodine
   Solifenacin
189 (58.0)
54 (16.6)
32 (9.8)
28 (8.6)
23 (7.0)
  
 10 mg (n = 104); 20 mg (n = 85)
2.5 mg (n = 8); 5 mg (n = 26);  
7.5 mg (n = 16); 10 mg (n = 4)
   2 mg (n = 9); 4 mg (n = 23)
   2 mg (n = 16); 4 mg (n = 12)
   5 mg (n = 23)
Average medication period  
   (months)
5.6 ± 7.3
Median follow-up (months)   9.8 ± 11.6
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RESULTS
Based on the 3-day bladder diaries, clinical efficacy were evalu-
ated on an exploratory basis. Among 326 children with lower 
urinary tract symptoms, 243 children (74.5%) had urgency symp-
tom and 158 children (48.5%) had UUI.
 On global questionnaire, 190 (78.2%) of 243 children with ur-
gency showed clinical improvement (no urgency) after anticho-
linergic treatment. UUI was improved (90% or over improved) 
in 125 (79.1%) of 158 children (Table 2). There were no signifi-
cant differences in improvement of urgency or UUI according 
to the types of anticholinergics (P = 0.139). UUI episodes per 
week had significantly decreased from 1.9 ± 3.1 to 0.4 ± 1.5 times 
(P < 0.001). 
 The mean voiding frequency during daytime was decreased 
from 9.2 ± 5.4 to 6.3 ± 4.2 times (P < 0.001). The numbers of fre-
quency episodes during daytime were all improved in 5 types 
of the drug. There were no significant differences in improve-
ment of frequency according to the types of anticholinergics 
(P = 0.207). 
 Both pretreatment and posttreatment 3-day voiding diaries 
were available in 104 children (mean age; 7.2 ± 2.7 yr). The maxi-
mum and average bladder capacity were increased from 145.5 
± 66.9 to 196.8 ± 80.3 mL and from 80.8 ± 39.6 to 121.8 ± 56.5 
mL, respectively (P < 0.001). 
 Analysis of uroflowmetry was available in 52 children. The 
maximum flow rate was increased from 17.6 ± 8.4 to 20.5 ± 8.2 
mL/sec (P < 0.001), whereas post-voiding residual volume was 
decreased from 24.4 to 14.3 mL (P < 0.001). The mean voiding 
volume was increased from 119.4 to 149.9 mL and it is statisti-
cally insignificant (P = 0.094).
 Adverse effects occurred in 14 (4.3%) children, including con-
stipation (n = 7), thirsty (n = 3), abdominal pain (n = 1), nausea 
(n = 1), dizziness (n = 1), and atopy (n = 1). Six children (1.8%) 
stopped medication due to the adverse effects (Table 3).
Table 3. Adverse effects
Adverse effects No. (%) Mild Moderate Severe
Discontinuation 
of drug
Constipation 7 (2.1) 3 (0.9) 4 (1.2) 2 (0.6)
Diarrhea 0
Abdominal pain 1 (0.3) 1 (0.3) 1 (0.3)
Indigestion 0
Nausea 1 (0.3) 1 (0.3) 1 (0.3)
Dryness of mouth 3 (0.9) 2 (0.6) 1 (0.3) 2 (0.6)
Rhinitis 0
Atopy 1 (0.3) 1 (0.3)
Dizziness 1 (0.3) 1 (0.3)
Fatigue/sleepiness 0
Visual disturbance 0
Headache 0
Total 14 (4.3) 5 (1.5) 8 (2.5) 1 (0.3) 6 (1.8)
Table 2. Efficacy of anticholinergics
Variables Pre-treatment Post-treatment Improvement P value
No. of urgency (%)
Propiverine
Oxybutynin
Solifenacin
Fesoterodine
Tolterodine
243
157
28
17
25
16
53 (21.8)
35 (22.3)
4 (14.3)
6 (35.3)
7 (28.0)
1 (6.2)
190 (78.2)
122 (77.7)
24 (85.7)
11 (64.7)
18 (72.0)
15 (93.8)
< 0.001
No. of urgency incontinence (%)
   Propiverine
   Oxybutynin
   Solifenacin
   Fesoterodin
   Tolterodine
158
102
16
9
19
12
33 (20.9)
20 (19.6)
0 (0)
3 (33.3)
7 (36.8)
2 (16.7)
125 (79.1)
82 (80.4)
16 (100)
6 (66.7)
12 (63.2)
10 (83.3)
< 0.001
Urgency incontinence (episode/week) 1.9 ± 3.1 0.4 ± 1.5 < 0.001
Frequency on voiding diary (n = 264*)  
   Propiverine (episode/day)
   Oxybutynin (episode/day)
   Solifenacin (episode/day)
   Fesoterodine (episode/day)
   Tolterodine (episode/day)
9.2 ± 5.4
10.1 ± 5.5
10.4 ± 4.9
8.8 ± 3.7
8.0 ± 3.5
6.8 ± 1.7
6.3 ± 4.2
6.6 ± 4.8
8.2 ± 2.8
6.7 ± 1.9
6.6 ± 1.8
5.8 ± 1.7
< 0.001
< 0.001
0.034
0.003
0.093
0.252
Bladder capacity (n = 104)
   Maximum capacity (mL)
   Average capacity (mL)
145.5 ± 66.9
80.8 ± 1.7
196.8 ± 80.3
121.8 ± 56.5
< 0.001
< 0.001
Uroflowmetry (n = 52)
   Voiding volume (mL)
   Maximum flow rate (mL/s)
   Residual urine (mL)
119.4 ± 117.6
17.6 ± 8.4
24.4 ± 72.2
149.9 ± 92.3
20.5 ± 8.2
14.3 ± 15.0
0.094
< 0.001
< 0.001
*One hundred and four children had frequency volume diaries before and after treatment. 160 children had only frequency check without volume information before or after 
treatment.
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DISCUSSION
OAB can have considerable impact on health-related quality of 
life (12). For adult OAB patients, various antimuscarinic drugs 
such as oxybutynin, propiverine, tolterodine, trospium chloride, 
and solifenacin have been introduced and are widely used with 
proven efficacy and stability. Pediatric OAB patients and their 
parents also experience difficulty in life. Not only can symptoms 
affect daily activities and productivity, but patients often have 
to deal with embarrassment and anxiety. The prevalence of 
OAB in Korean children between 5-13 yr old is reported to be 
16.59% which is relatively high although it is lower than that of 
adults (13). While treatment is necessary in these patients, the 
treatment failure is substantial and anticholinergic treatment 
efficacy varies from 65 to 75% (14). Therefore, various anticho-
lingergic drugs as the first or secondary treatments should also 
be needed for pediatric OAB patients like adult OAB patients. 
Through the current study, many urologic or pediatric doctors 
come out into the use various anticholinergics in practice. Prop-
iverine (58%) was the most favorite anticholinergic agent in Ko-
rean pediatric doctors. Oxybutynin was still the second most 
used drug due to Korean national insurance. Half dose (10 mg) 
and old distribution in adult OAB patients may make propiver-
ine the most favorite drug. 
 Currently, oxybutynin chloride is the only FDA-approved an-
timuscarinic drug licensed for use in pediatric patients in Ko-
rea. Moreover, oxybutynin extended release (ER) rather than 
oxybutynin immediate release (IR) is widely administered be-
cause of fewer adverse effects. Oxybutynin ER is only available 
in tablet form, which is difficult for infants and toddlers to swal-
low (15). Although several anticholinergics should be clinically 
used in the management of OAB for pediatric patients refracto-
ry to oxybutynin, use of antimuscarinic medications for treat-
ment of OAB has not been studied as extensively in children as 
it has in adults. Therefore, it is very important that clinicians 
understand the efficacy and safety of various anticholinergics, 
which inevitably could be used in clinical practice. For this rea-
son more studies about safety and tolerability of various anti-
cholinergics for pediatric OAB patients are needed. Our study 
contains important information and clinical results in the cur-
rent situations. In the current study, 78.2% of 243 children with 
urgency showed clinical improvement (no urgency) after anti-
cholinergic treatment. UUI was improved (90% or over improved) 
in 79.1% of 158 children. These response rates are similar to those 
of previous studies (6, 15). There were no significant differences 
in improvement of urgency or UUI according to the types of an-
ticholinergics. UUI episodes per week had significantly decreas-
ed from 1.9 ± 3.1 to 0.4 ± 1.5 times (P < 0.001).
 The Korean Children’s Continence and Enuresis Society re-
ported maximum bladder capacity of healthy 219 children, aged 
3 to 13 yr without history of voiding disorder was 232.7 ± 84.6 
mL (range, 161-301 mL) (16). In the current study, the maximum 
bladder capacity was significantly increased from 145.5 ± 66.9 
to 196.8 ± 80.3 mL. Although symptom improved in current 
OAB patients and the age of healthy population was younger 
than that of current study, the maximum bladder capacity after 
anticholinergic treatment was still smaller than that of healthy 
population. 
 Adverse effects were reported in only 14 patients, and one 
patients experienced severe dry mouth and the medication was 
stopped. The medication was discontinued due to moderate 
symptoms in 5 patients. Most of adverse effects in the current 
study were less frequent than those in adult OAB patients (15, 17). 
 Our study has several limitations. First, it was an uncontrolled 
retrospective study. The potential for bias existed in the patient 
selection because children with a relatively good compliance 
with medication were included. Second, we included various 
anticholinergic drugs with uncontrolled drug dosage. Third, we 
do not know whether each patient underwent standard uro-
therapy or not. Standard urotherapy itself might have improved 
OAB symptoms. Finally, the reported complications may be rel-
atively lower than actual occurrence because it is possible that 
all the complications might not have written on the medical re-
cords. In reality, it is unlikely for doctors to ask the patients and 
their parents about adverse effects in detail unless the study is 
conducted as a planned prospective study. Despite these limi-
tations, our study results contain important and practical infor-
mation for anticholinergic drug treatment in children with OAB. 
According to the current study results, anticholinergics have a 
good efficacy and are well tolerated for children suffering from 
OAB. On the basis of our study result, we hope that effectiveness 
and safety of antimuscarinics for pediatric OAB patients are clear-
ly demonstrated by large-scale, prospective, and randomized 
studies in the future. 
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